Collateral for a security interest recorded Jul 13, 2026 (Biopharma Credit PLC).
Term ends Oct 31, 2040 · High confidence
20-year base term ends Jun 19, 2040
Held by Esperion Therapeutics, Inc.
Filed Aug 16, 2023 as application 18/450,591 · Granted Sep 2, 2025
Base term plus 134 days of patent term adjustment (USPTO delay)
Today
2020
2040
Clock starts
Jun 19, 2020
Jun 19, 2020
Term ends
Oct 31, 2040
Oct 31, 2040
Granted
Sep 2, 2025
Sep 2, 2025
base term
patent term adjustment
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
134
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
12
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 134 days past its 20-year base term on prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 19, 2020, when application PCT/US2020/038622, the earliest non-provisional in its chain, was filed (this one was filed Aug 16, 2023) | Jun 19, 2040 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +134 days, USPTO patent term adjustment record | Oct 31, 2040 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 31, 2040 | High confidence |
This family
| Application PCT/US2020/038622 | PCT application no patent term | no patent term |
| Application 17/150,321 | Abandoned not computed | not computed |
| US 11,407,705 | In force Jun 2040 | Jun 2040 |
| US 11,760,714 | In force Jun 2040 | Jun 2040 |
| US 11,613,511 | In force Jun 2040 | Jun 2040 |
| US 11,987,548 | In force no later than Jun 2040 | no later than Jun 2040 |
| US 11,926,584 | In force no later than Jun 2040 | no later than Jun 2040 |
| US 12,404,227 | this patent Oct 2040 | Oct 2040 |
8 of 12 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 8, 2024 Reel 66048, frame 362 | Abdelnasser, Mohamed | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 513 | Copp, Richard; Cimarusti, Christopher M. | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 529 | Selig, Philipp | Patheon Austria GmbH & Co. KG | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 540 | Patheon Austria GmbH & Co. KG | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 561 | Lane, Jonathan; Barkman, Michael; Amin, Rasidul; Frank, Michelle | Corden Pharma Colorado, Inc. | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 570 | Corden Pharma Colorado, Inc. | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 576 | Cooper, Arthur John; Gopal, Damodaragounder | Olon Ricerca Bioscience LLC | Assignment of Assignor's Interest |
| Jan 8, 2024 Reel 66048, frame 583 | Olon Ricerca Bioscience LLC | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Dec 13, 2024 Reel 69582, frame 756 | Esperion Therapeutics, Inc. | Glas Americas LLC | Security Interest |
| Jul 13, 2026 Reel 75952, frame 812 | Esperion Therapeutics, Inc.; Resq Pharmaceuticals LLC | Biopharma Credit PLC, as Collateral Agent | Patent Security Agreement |
| Jul 14, 2026 Reel 75267, frame 816 | Glas Americas LLC | Esperion Therapeutics Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2040
Term ends Oct 31, 2040. Maintenance fees still fall due before then
Note
The 134 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
0
later US patents cite this one
Fewer than half of the utility patents granted in 2025 in our data have been cited yet, so we show the count and do not rank on it.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.